Skip to main content

DNA deletion disease syndromes

Characterizing the spectrum of mitochondrial DNA deletion disease syndromes


Researchers from the Mitochondrial Medicine Program at Children's Hospital of Philadelphia (CHOP) have better characterized a spectrum of what were classically considered discrete mitochondrial DNA deletion disease syndromes. The findings offer new insights into genetic causes, potential symptoms, and disease progression, and may inform future clinical trial development. The findings were published today in the journal Genetics in Medicine.

Mitochondrial disease refers to a group of disorders that affect the mitochondria, which are tiny compartments present in almost every cell of the body that generate most of our energy. Certain forms of mitochondrial disease – Pearson syndrome, Kearns-Sayre syndrome (KSS) and chronic progressive external ophthalmoplegia (CPEO) – are each caused by single large-scale mitochondrial DNA (mtDNA) deletions (SLSMD), which involve the loss of a large segment within the small DNA genome that is found exclusively in the mitochondria.

While the genetic cause of these SLSMD syndromes is similar, the affected tissues and clinical presentations can vary wildly. Pearson syndrome is typically diagnosed in infancy due to growth failure and anemia; KSS might develop as progressive multi-system symptoms during mid-childhood; and CPEO typically presents in adults with eye muscle movement problems. Understanding the natural history study of these rare diseases is particularly challenging because so few patients are diagnosed in any stage and some cases can lead to early death.

To better understand SLSMD's molecular and clinical scope, researchers compiling information and data from 30 known cases seen at CHOP between 2002 and 2020 was performed using modern techniques for analyzing electronic medical records to more quickly and nimbly conduct a retrospective natural history study.

"Although these are the three named syndromic phenotypes in the spectrum SLSMD syndromes, the spectrum is actually broader and includes patients whose symptoms do not meet any of their strict diagnostic criteria," said first study author Rebecca Ganetzky, M.D., an attending physician in Mitochondrial Medicine and the Director of Mitochondrial Biochemical Diagnostic Test Development at CHOP. "This retrospective natural history study was designed more accurately inform the spectrum of clinical presentation for SLSMD disorders. This will enable future clinical trials to enroll a greater range of patients and evaluate a wider range of clinical endpoints that effectively describe symptom and quality of life effects in meaningful ways to patients across the disease spectrum."

Many of these patients share certain molecular details. For example, this study found that a recurrent deleted region within the gene MT-ND5 occurred in 96% of SLSMD patients, regardless of their eventual clinical phenotype, which tended to evolve from one category to the next in certain patients over time. Additionally, the biomarker peptide growth differentiation factor 15 (GDF-15) was highly elevated in all SLSMD patients in this study, regardless of clinical features. Higher levels in blood of SLSMD heteroplasmy– a phenomenon unique to mtDNA reflecting the presence of both normal and deleted genomes in a patient – correlated with earlier age of disease onset. As a patient's age increased, greater fatigue and lower quality of life were reported.

This study was supported in part by an investigator-initiated sponsored research award from Minovia Therapeutics and from the Children's Hospital of Philadelphia Mitochondrial Medicine Frontier Program.

DNA deletion, genetic mutation, genome editing, chromosomal aberration, gene loss, genetic disorder, DNA repair, genetic variation, CRISPR-Cas9, genetic recombination, hereditary disease, DNA sequencing, mutation analysis, exon deletion, genomic instability, structural variation, genetic abnormality, frameshift mutation, molecular genetics, pathogenic mutation,

#DNADeletion #GeneticMutation #GenomeEditing #ChromosomalAberration #GeneLoss #GeneticDisorder #DNARepair #GeneticVariation #CRISPRCas9 #GeneticRecombination #HereditaryDisease #DNASequencing #MutationAnalysis #ExonDeletion #GenomicInstability #StructuralVariation #GeneticAbnormality #FrameshiftMutation #MolecularGenetics #PathogenicMutation

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: genetics@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Popular posts from this blog

Genetics role in ovarian cancer

The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...

Migration in Population Genetics

  Migration in Population Genetics Migration in population genetics refers to the movement of individuals-and therefore their genes -between different populations of the same species. This gene flow alters allele frequencies, increasing genetic diversity within populations while reducing genetic differences between them. Migration can counteract the effects of genetic drift and inbreeding , introduce new alleles , and influence evolutionary processes such as adaptation and natural selection. The rate, direction, and scale of migration play a crucial role in shaping population structure, evolutionary potential, and long-term species survival, especially in fragmented habitats or changing environments. Migration, Population Genetics, Gene Flow, Allele Frequency, Genetic Diversity, Evolution, Genetic Variation, Population Structure, Adaptation, Biodiversity #PopulationGenetics #Migration #GeneFlow #GeneticDiversity #EvolutionaryBiology #AlleleFrequency #NaturalSelection #GeneticD...

Chromosomal Abnormalities

  Chromosomal Abnormalities Chromosome abnormalities refer to structural or numerical changes in chromosomes that can disrupt normal genetic function, leading to developmental disorders, congenital abnormalities, and various genetic diseases. These abnormalities may arise from errors in cell division, such as nondisjunction or chromosomal breakage, resulting in conditions like Down syndrome , Turner syndrome, Klinefelter syndrome , and various deletion or duplication syndromes. Understanding chromosome abnormalities is essential for genetic counseling, prenatal diagnosis, disease risk assessment, and research in cytogenetics and molecular genetics. Chromosome abnormalities, chromosomal disorders, chromosomal mutations, aneuploidy, structural chromosome abnormalities, nondisjunction, deletion syndrome, duplication syndrome , translocation, inversion, cytogenetics, karyotyping, prenatal diagnosis , genetic testing, genomic instability, Down syndrome, Turner syndrome, Klinefelter syn...